Login to Your Account



Earnings Roundup


Monday, July 18, 2011
Cubist Pharmaceuticals Inc., of Lexington, Mass., reported second quarter net U.S. sales of $168.6 million for antibiotic Cubicin (daptomycin), while the firm's net product revenues from international sales were $7.7 million. The company reported total net revenue of $176.8 million, up 9 percent over the same quarter in 2010. Net loss was $20.6 million, or 34 cents per share, far below consensus estimates, which had predicted net income earnings per share of 41 cents.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription